Brandes Investment Partners, LP United Therapeutics Corp Transaction History

Brandes Investment Partners, LP

  • $8.37 Billion
  • Q3 2024

A detailed history of Brandes Investment Partners, LP transactions in United Therapeutics Corp stock. As of the latest transaction made, Brandes Investment Partners, LP holds 11,694 shares of UTHR stock, worth $4.18 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
11,694
Previous 19,916 41.28%
Holding current value
$4.18 Million
Previous $6.34 Million 33.95%
% of portfolio
0.05%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$311.04 - $363.55 $2.56 Million - $2.99 Million
-8,222 Reduced 41.28%
11,694 $4.19 Million
Q2 2024

Aug 19, 2024
BUY
$228.26 - $319.04 $211,368 - $295,431
926 Added 4.88%
19,916 $6.34 Million
Q1 2024

May 15, 2024
BUY
$210.76 - $249.51 $610,571 - $722,830
2,897 Added 18.0%
18,990 $4.36 Million
Q4 2023

Feb 09, 2024
BUY
$214.88 - $256.94 $189,953 - $227,134
884 Added 5.81%
16,093 $3.54 Million
Q3 2023

Nov 13, 2023
BUY
$211.82 - $248.24 $145,943 - $171,037
689 Added 4.75%
15,209 $3.44 Million
Q2 2023

Aug 11, 2023
SELL
$205.19 - $232.99 $22,570 - $25,628
-110 Reduced 0.75%
14,520 $3.21 Million
Q1 2023

May 10, 2023
BUY
$212.99 - $276.17 $994,663 - $1.29 Million
4,670 Added 46.89%
14,630 $3.28 Million
Q4 2022

Feb 13, 2023
SELL
$205.95 - $280.43 $1.97 Million - $2.68 Million
-9,546 Reduced 48.94%
9,960 $2.77 Million
Q3 2022

Nov 14, 2022
SELL
$203.3 - $244.17 $325,076 - $390,427
-1,599 Reduced 7.58%
19,506 $4.08 Million
Q2 2022

Aug 12, 2022
BUY
$174.81 - $241.14 $191,591 - $264,289
1,096 Added 5.48%
21,105 $4.97 Million
Q1 2022

May 10, 2022
BUY
$166.16 - $213.96 $237,941 - $306,390
1,432 Added 7.71%
20,009 $3.59 Million
Q4 2021

Feb 11, 2022
SELL
$184.32 - $216.08 $50,872 - $59,638
-276 Reduced 1.46%
18,577 $4.02 Million
Q3 2021

Nov 12, 2021
BUY
$179.86 - $214.88 $85,613 - $102,282
476 Added 2.59%
18,853 $3.48 Million
Q2 2021

Aug 11, 2021
SELL
$170.47 - $211.93 $2,045 - $2,543
-12 Reduced 0.07%
18,377 $3.3 Million
Q1 2021

May 14, 2021
SELL
$153.94 - $174.85 $2.18 Million - $2.47 Million
-14,148 Reduced 43.48%
18,389 $3.04 Million
Q4 2020

Feb 11, 2021
SELL
$101.87 - $151.79 $2.78 Million - $4.14 Million
-27,255 Reduced 45.58%
32,537 $4.84 Million
Q3 2020

Nov 12, 2020
SELL
$99.9 - $121.13 $1.66 Million - $2.01 Million
-16,571 Reduced 21.7%
59,792 $6.04 Million
Q2 2020

Aug 12, 2020
SELL
$92.74 - $125.82 $20 Million - $27.2 Million
-216,033 Reduced 73.88%
76,363 $9.24 Million
Q1 2020

May 13, 2020
BUY
$79.39 - $115.35 $112,257 - $163,104
1,414 Added 0.49%
292,396 $27.7 Million
Q4 2019

Feb 13, 2020
SELL
$78.31 - $95.34 $480,118 - $584,529
-6,131 Reduced 2.06%
290,982 $25.6 Million
Q3 2019

Nov 13, 2019
BUY
$74.85 - $85.99 $5.61 Million - $6.45 Million
74,963 Added 33.74%
297,113 $23.7 Million
Q2 2019

Aug 13, 2019
BUY
$76.06 - $120.81 $13.4 Million - $21.3 Million
176,048 Added 381.87%
222,150 $17.3 Million
Q1 2019

May 10, 2019
BUY
$107.15 - $126.84 $238,623 - $282,472
2,227 Added 5.08%
46,102 $5.41 Million
Q4 2018

Feb 11, 2019
BUY
$101.4 - $128.73 $1.53 Million - $1.95 Million
15,111 Added 52.53%
43,875 $4.78 Million
Q3 2018

Nov 09, 2018
SELL
$113.81 - $129.46 $115,061 - $130,884
-1,011 Reduced 3.4%
28,764 $3.68 Million
Q2 2018

Aug 13, 2018
BUY
$101.14 - $118.31 $287,743 - $336,591
2,845 Added 10.56%
29,775 $3.37 Million
Q1 2018

May 15, 2018
BUY
$107.21 - $151.94 $1.42 Million - $2.01 Million
13,217 Added 96.38%
26,930 $3.03 Million
Q4 2017

Feb 12, 2018
BUY
$118.58 - $151.28 $1.63 Million - $2.07 Million
13,713
13,713 $2.03 Million

Others Institutions Holding UTHR

# of Institutions
671
Shares Held
42.3M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.3B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Brandes Investment Partners, LP Portfolio

Follow Brandes Investment Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandes Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Brandes Investment Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email